Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 638

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 638
---
 “ Capital Increase ”), will be carried out which will be based on a resolution passed at an extraordinary general meeting (the “ EGM ”) that requires the approval of 67% of the shareholders voting at the EGM, for the purpose of making available the required number of shares of Parent Common Stock to serve as Merger Consideration (the “ Merger Shares ”). (b) After the approval of the Capital Increase and sufficiently prior to the actions described under Section 5.6.3(c) , but in any event no later than five (5) Business Days prior to the date of the Parent Board Meeting (as defined below), the following shall be performed: (i) The Parties shall cause Exchange Agent to subscribe for the Merger Shares by delivering the corresponding subscription forms, duly executed (wet-ink) and in form and substance satisfactory to Parent (the “ Subscription Forms ”). (ii) If and to the extent that the settlement of the Merger Shares will be in cash, the Company shall procure that the Exchange Agent will pay in, for account of the Company, the nominal value in Swiss francs (CHF) for each Merger Share (CHF 0.80 per share or such other nominal value as may be adopted) settled in cash by electronic wire transfer (without deductions of bank charges and transfer costs) to the following special purpose blocked capital account of a Swiss bank in favor of Parent ( Kapitaleinzahlungssperrkonto ) in the name of Parent:

| Account Holder:     |     | NLS Pharmaceutics AG                             |
| USD Account Number: |     | 206 -196654.61Q                                  |
| IBAN:               |     | CH72 0020 6206 1966 5461 Q                       |
| Bank Name:          |     | UBS SWITZERLAND AG                               |
| Bank Address:       |     | Bahnhofstrasse 45                                |
|                     |     | CH-8098 Zürich                                   |
| BIC/SWIFT:          |     | UBSWCHZH80A                                      |
| Reference:          |     | Share Capital Increase of NLS Pharmaceutics Ltd. |

Annex A-39 (iii) The Parties shall cause the Swiss bank to immediately issue a written confirmation evidencing that the nominal value for each Merger Share that was settled in cash in accordance with Section 5.6.3(b)(ii) above, has been fully credited